Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard Health Care ETF (NY:VHT)

269.00 -0.31 (-0.12%)
Official Closing Price Updated: 6:30 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vanguard Health Care ETF

< Previous 1 2 3 Next >
How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline
Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on. 
Via Benzinga
Topics ETFs Government
The Healthcare Stock Play That Could Make Millennials Rich
This investment may also make baby boomers, and those from Gen X and Gen Z, rich as well. 
Via The Motley Fool
Topics ETFs
Trump Admin Targets Medicaid Spending On Immigrants, Threatening Over $12 Billion California Program
The Trump administration is investigating Medicaid spending in California and other Democrat-led states over potential misuse in immigrant healthcare programs. 
Via Benzinga
Topics Government
Trump-nominee Susan Monarez Confirmed As CDC Director By Senate
According to a report by Reuters, the Senate voted 51-47 along party lines to confirm the President’s nominee. 
Via Stocktwits
Topics Government Workforce
Here's Why Vanguard's Worst-Performing Sector ETF Is a No-Brainer Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence ETFs
US Supreme Court Reportedly Upholds Part Of Obamacare That Guarantees Health Insurers Cover Preventive Care
The Obamacare law requires health insurers to provide preventive care, including cancer screenings and HIV prevention medication, at no cost to patients. 
Via Stocktwits
Topics Government Lawsuit Religion
UnitedHealth Reportedly Draws Bids Worth $1B For Banmedica In Latin America Exit
According to Reuters, UnitedHealth has received four preliminary bids for Banmedica and could set a deadline for binding offers as early as July. 
Via Stocktwits
Topics Fraud
Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment
Both trials were conducted during the COVID-19 pandemic, a factor the companies said may have influenced the outcomes. 
Via Stocktwits
Topics Government Stocks
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled
BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday. 
Via Stocktwits
Creating A Sector-Based ETF Portfolio
A sector-based ETF portfolio provides an effective way to navigate these market rhythms, allowing investors to position their assets for potential outperformance. 
Via Talk Markets
Topics ETFs
RFK Jr.'s Massive Federal Health Workforce Cut Could Take 'Decades To Rebuild,' Warn Experts: 'We Cannot Accurately Assess Whether We Are Truly Making America Healthier'
Experts raise alarms about Health Secretary Robert F. Kennedy Jr's decision to layoff tens of thousands of federal workers, disrupting critical health data collection and research efforts. 
Via Benzinga
Topics Workforce
As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs
ETFs that provide exposure to sectors that have historically been considered defensive during downturns are now in the limelight. 
Via Benzinga
Topics ETFs Government
Best Blue-Chip ETFs To Buy As Donald Trump’s Trade War Escalates
Investing in defensive ETFs may be a good way to weather the storm. 
Via Talk Markets
Topics ETFs Government World Trade
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals
Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue... 
Via Stocktwits
Topics Bankruptcy
HealthEquity Stock Sees Biggest Drop In Over 3 Years On Disappointing Outlook — Retail Doesn't Feel It's All Doom And Gloom
CFO James Lucania said on the earnings call that fraud prevention efforts are ongoing, and service expenses are expected to remain elevated through the first half of fiscal 2026. 
Via Stocktwits
Topics Earnings Fraud
Trump Tariffs and the Nasdaq Correction Have Been No Match for These Stock Market Sectors
Via The Motley Fool
Topics Government
Healthcare Sector Trying To Bounce Back
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector. 
Via Talk Markets
Topics ETFs Stocks / Equities
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates
Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years. 
Via Stocktwits
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars?
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as... 
Via Talk Markets
Topics ETFs Stocks / Equities
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
Prediction: 2 Brilliant Vanguard Index Funds Will Continue to Beat the S&P 500 in 2025
Via The Motley Fool
Topics Stocks
Hims & Hers Stock Sinks After-Hours As Weight-Loss Roadmap Gets Clouded — Retail Pounces On The Dip
On the earnings call, CEO Andrew Dudum acknowledged that the transition would be "inevitable" for patients currently on compounded semaglutide. 
Via Stocktwits
Topics Earnings
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
CEO Andrew Dudum acknowledged retail shareholders in a post on X, highlighting their deep research on the company and announcing plans to engage them directly on future earnings calls. 
Via Stocktwits
Hims & Hers Hits New Highs On At-Home Lab Testing Plans: Retail Sees More Room To Run, Analysts Divided
One analyst warned that elevated growth expectations could lead to near-term volatility as the company introduces its FY25 guidance. 
Via Stocktwits
Hims & Hers Stock: More Gains Ahead Or A Pullback? Most Retail Traders Bet On This Path
A poll of over 4,000 respondents found that 47% believe the stock will continue its climb past $60, while 44% expect a significant pullback for profit-taking. 
Via Stocktwits
US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget
A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21. 
Via Benzinga
Prediction: The 2 Best Vanguard Index Funds in January Will Beat the S&P 500 in 2025
Via The Motley Fool
Topics Stocks
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.